Loading patent…
AssigneeCorixa Corporation
InventorsAlexander Gaiger, Molly D. Smithgall, Darrick Carter, Martin A. Cheever, Patricia D. McNeill, R. Alec Sutherland, Sally P. Mossman, Lawrence S. Evans, Ryan M. Swanson
Estimating the term…
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
A method for inducing an immune response in an animal, comprising:
A method for treating a malignancy associated with WT1 expression in a patient, comprising administering to the patient a composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising at least an immungenic portion of a WT1 polypeptide.
An isolated polypeptide comprising at least an immunogenic portion of the WT1 protein, wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO:241.
An isolated polypeptide comprising at least an immunogenic portion of a WT1 polypeptide, wherein said immunogenic portion comprises an amino acid sequence selected from the group consisting of:
A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:
An isolated polypeptide comprising an amino acid sequence of any one of SEQ ID NOs:454-455.
Dependencies are inferred from the claim text.